543 lines
No EOL
91 KiB
HTML
543 lines
No EOL
91 KiB
HTML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK604930" /><meta name="ncbi_domain" content="nciprotocols" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK604930/" /><meta name="ncbi_pagename" content="Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]" /><meta name="citation_title" content="Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology" /><meta name="citation_publisher" content="National Cancer Institute (US)" /><meta name="citation_date" content="2022/09" /><meta name="citation_author" content="Stern Stephan T." /><meta name="citation_pmid" content="39013071" /><meta name="citation_doi" content="10.17917/W63A-GR02" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK604930/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Cancer Institute (US)" /><meta name="DC.Contributor" content="Stern Stephan T." /><meta name="DC.Date" content="2022/09" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK604930/" /><meta name="description" content="Novel nanoformulated chemotherapeutics and diagnostics require demonstration of efficacy and safety in appropriate animal models prior to clinical translation of the concept. Pharmacokinetic studies are also important to optimize dosing regimen and dose escalation strategy, and identify potential species differences. NCL’s in vivo experiments are tailored specifically to the individual nanoparticle under study. As such, a standard experimental protocol cannot be generated. Instead of a protocol, we offer the following general guidance for experimental design and data analysis. The following description is not a protocol and does not describe all of the relevant experimental parameters necessary to conduct the experiment. If you would like additional information, please feel free to contact us." /><meta name="og:title" content="Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology" /><meta name="og:type" content="book" /><meta name="og:description" content="Novel nanoformulated chemotherapeutics and diagnostics require demonstration of efficacy and safety in appropriate animal models prior to clinical translation of the concept. Pharmacokinetic studies are also important to optimize dosing regimen and dose escalation strategy, and identify potential species differences. NCL’s in vivo experiments are tailored specifically to the individual nanoparticle under study. As such, a standard experimental protocol cannot be generated. Instead of a protocol, we offer the following general guidance for experimental design and data analysis. The following description is not a protocol and does not describe all of the relevant experimental parameters necessary to conduct the experiment. If you would like additional information, please feel free to contact us." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK604930/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-nciprotocols-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/nciprotocols/ncipr78/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK604930/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/core/mathjax/2.7.9/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script><meta name="book-collection" content="NONE" />
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8DCB107C80A1A10000000000040003.m_13" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/4207974/4206132/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-part">
|
||
<div class="grid">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
<div id="universal_header">
|
||
<section class="usa-banner">
|
||
<div class="usa-accordion">
|
||
<header class="usa-banner-header">
|
||
<div class="usa-grid usa-banner-inner">
|
||
<img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
|
||
<p>An official website of the United States government</p>
|
||
<button class="non-usa-accordion-button usa-banner-button" aria-expanded="false" aria-controls="gov-banner-top" type="button">
|
||
<span class="usa-banner-button-text">Here's how you know</span>
|
||
</button>
|
||
</div>
|
||
</header>
|
||
<div class="usa-banner-content usa-grid usa-accordion-content" id="gov-banner-top" aria-hidden="true">
|
||
<div class="usa-banner-guidance-gov usa-width-one-half">
|
||
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg" alt="Dot gov" />
|
||
<div class="usa-media_block-body">
|
||
<p>
|
||
<strong>The .gov means it's official.</strong>
|
||
<br />
|
||
Federal government websites often end in .gov or .mil. Before
|
||
sharing sensitive information, make sure you're on a federal
|
||
government site.
|
||
</p>
|
||
</div>
|
||
</div>
|
||
<div class="usa-banner-guidance-ssl usa-width-one-half">
|
||
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg" alt="Https" />
|
||
<div class="usa-media_block-body">
|
||
<p>
|
||
<strong>The site is secure.</strong>
|
||
<br />
|
||
The <strong>https://</strong> ensures that you are connecting to the
|
||
official website and that any information you provide is encrypted
|
||
and transmitted securely.
|
||
</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
<div class="usa-overlay"></div>
|
||
<header class="ncbi-header" role="banner" data-section="Header">
|
||
|
||
<div class="usa-grid">
|
||
<div class="usa-width-one-whole">
|
||
|
||
<div class="ncbi-header__logo">
|
||
<a href="/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
|
||
<img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
|
||
</a>
|
||
</div>
|
||
|
||
<div class="ncbi-header__account">
|
||
<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
|
||
<button id="account_info" class="header-button" style="display:none" aria-controls="account_popup" type="button">
|
||
<span class="fa fa-user" aria-hidden="true">
|
||
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="20px" height="20px">
|
||
<g style="fill: #fff">
|
||
<ellipse cx="12" cy="8" rx="5" ry="6"></ellipse>
|
||
<path d="M21.8,19.1c-0.9-1.8-2.6-3.3-4.8-4.2c-0.6-0.2-1.3-0.2-1.8,0.1c-1,0.6-2,0.9-3.2,0.9s-2.2-0.3-3.2-0.9 C8.3,14.8,7.6,14.7,7,15c-2.2,0.9-3.9,2.4-4.8,4.2C1.5,20.5,2.6,22,4.1,22h15.8C21.4,22,22.5,20.5,21.8,19.1z"></path>
|
||
</g>
|
||
</svg>
|
||
</span>
|
||
<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
|
||
<span class="sr-only">Show account info</span>
|
||
</button>
|
||
</div>
|
||
|
||
<div class="ncbi-popup-anchor">
|
||
<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
|
||
<div class="ncbi-popup-head">
|
||
<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu" type="button">
|
||
<span class="fa fa-times">
|
||
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" height="24px">
|
||
<path d="M38 12.83l-2.83-2.83-11.17 11.17-11.17-11.17-2.83 2.83 11.17 11.17-11.17 11.17 2.83 2.83 11.17-11.17 11.17 11.17 2.83-2.83-11.17-11.17z"></path>
|
||
</svg>
|
||
</span>
|
||
<span class="usa-sr-only">Close</span></button>
|
||
<h4>Account</h4>
|
||
</div>
|
||
<div class="account-user-info">
|
||
Logged in as:<br />
|
||
<b><span class="username" id="uname_long">username</span></b>
|
||
</div>
|
||
<div class="account-links">
|
||
<ul class="usa-unstyled-list">
|
||
<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
|
||
<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
|
||
<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
|
||
<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
</header>
|
||
<div role="navigation" aria-label="access keys">
|
||
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
|
||
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
|
||
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
|
||
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
|
||
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
|
||
</div>
|
||
<section data-section="Alerts">
|
||
<div class="ncbi-alerts-placeholder"></div>
|
||
</section>
|
||
</div>
|
||
<div class="header">
|
||
<div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
|
||
<div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" data-ac_dict="bookshelf-search">Books</option><option value="refseq">RefSeq</option><option value="nuccore">Nucleotide</option><option value="clinvar" class="last">ClinVar</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
|
||
<a href="/books/browse/">Browse Titles</a>
|
||
</li><li>
|
||
<a href="/books/advanced/">Advanced</a>
|
||
</li><li class="help">
|
||
<a href="/books/NBK3833/">Help</a>
|
||
</li><li class="disclaimer">
|
||
<a target="_blank" data-ga-category="literature_resources" data-ga-action="link_click" data-ga-label="disclaimer_link" href="https://www.ncbi.nlm.nih.gov/books/about/disclaimer/">Disclaimer</a>
|
||
</li></ul></div>
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<!-- Custom content 1 -->
|
||
<div class="col1">
|
||
|
||
</div>
|
||
|
||
<div class="container">
|
||
<div id="maincontent" class="content eight_col col">
|
||
<!-- Custom content in the left column above book nav -->
|
||
<div class="col2">
|
||
|
||
</div>
|
||
|
||
<!-- Book content -->
|
||
|
||
|
||
<!-- Custom content between navigation and content -->
|
||
<div class="col3">
|
||
|
||
</div>
|
||
|
||
<div class="document">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1-. doi: 10.17917/W63A-GR02</p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="Table of Contents Page" href="/books/n/nciprotocols/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-nciprotocols-lrg.png" alt="Cover of National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK604930_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK604930_dtls__"><div>Bethesda (MD): <a href="https://www.cancer.gov/nano/research/ncl" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>; 2005 May 1-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/nciprotocols/">Contents</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/nciprotocols/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/nciprotocols/ncipr18/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/nciprotocols/ncipr32/" title="Next page in this title">Next ></a></div></div></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK604930_"><span class="title" itemprop="name">Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology</span></h1><p class="contrib-group"><span itemprop="author">Stern Stephan T.</span></p><p class="small">Published: <span itemprop="datePublished">September 2022</span>.</p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ncipr78.s1"><h2 id="_ncipr78_s1_">Introduction</h2><p>Novel nanoformulated chemotherapeutics and diagnostics require demonstration of efficacy and safety in appropriate animal models prior to clinical translation of the concept. Pharmacokinetic studies are also important to optimize dosing regimen and dose escalation strategy, and identify potential species differences. NCL’s in vivo experiments are tailored specifically to the individual nanoparticle under study. As such, a standard experimental protocol cannot be generated. Instead of a protocol, we offer the following general guidance for experimental design and data analysis. The following description is <b>not</b> a protocol and does not describe all of the relevant experimental parameters necessary to conduct the experiment. If you would like additional information, please feel free to contact us.</p><blockquote><p><b><i>Note</i></b> : <i>FNLCR is accredited by AAALAC International and follows the Public Health Service Policy for the Care and Use of Laboratory Animals (Health Research Extension Act of 1985, Public Law 99-158, 1986). Animal care is provided in accordance with the procedures outlined in the Guide for Care and Use of Laboratory Animals (National Research Council, 1996; National Academy Press, Washington, D.C.). All animal protocols are approved by the FNL Institutional Animal Care and Use Committee (IACUC). Any experiments performed are scientifically justified and are not an unnecessary duplication of previous work by others</i>.</p></blockquote></div><div id="ncipr78.s2"><h2 id="_ncipr78_s2_">Efficacy Studies</h2><div id="ncipr78.s2.1"><h3>1. NCL Capabilities: In Vivo Efficacy Studies Utilizing Rodent Models</h3><p>In vivo efficacy studies at NCL are performed in collaboration with FNL’s Laboratory Animal Science Program. NCL efficacy studies utilize transgenic, chemically induced, syngeneic, or xenograft tumor models to provide independent verification of collaborators’ proof-of-concept studies. Here are some of the models we have experience with:
|
||
<ul class="simple-list"><li class="half_rhythm"><div class="half_rhythm"><u>Tumor Models</u>
|
||
<ul class="simple-list"><li class="half_rhythm"><div><b>Subcutaneous Models:</b>
|
||
<ul><li class="half_rhythm"><div>LS174T colon cancer model</div></li><li class="half_rhythm"><div>MDA-MB-231 breast cancer model</div></li><li class="half_rhythm"><div>MCF-7 estrogen-dependent breast cancer model</div></li><li class="half_rhythm"><div>LOX IMVI melanoma model</div></li><li class="half_rhythm"><div>HCT116 colon cancer model</div></li><li class="half_rhythm"><div>We also have access to the following xenografts under our current animal study protocols (ASP): B16, BALB/3T3, NIH/3T3, N87, SKOV3, KB-DTP, KB-ATCC, and UM SCC-81B. We can obtain approval for other cell lines, but this process can take several weeks.</div></li></ul></div></li><li class="half_rhythm"><div><b>Orthotopic Models:</b>
|
||
<ul><li class="half_rhythm"><div>MDA-MB-231 breast cancer model</div></li><li class="half_rhythm"><div>4T1 breast cancer model</div></li><li class="half_rhythm"><div>Intracranial injection of U87 (human)/ TRE (murine) glioma cell lines (in collaboration with FNL’s Center for Advance Preclinical Research (CAPR))</div></li></ul></div></li><li class="half_rhythm"><div><b>Metastatic Models:</b>
|
||
<ul><li class="half_rhythm"><div>Metastasis of mammary pad MDA-MB-231-Luc/4T1-Luc cell line to lymph node and lung</div></li><li class="half_rhythm"><div>Metastasis of intradermal B16-F10 to lymph node</div></li><li class="half_rhythm"><div>Lung metastasis model (via intravenous injection of B16-F10-Luc cancer cell line)</div></li><li class="half_rhythm"><div>Peritoneal cavity metastasis model (via intraperitoneal injection of ID8-Luc ovarian cancer cell line)</div></li><li class="half_rhythm"><div>Metastasis to the brain (via left ventricle injection of brain seeking MDA-MB-231 Br breast cancer cell line)</div></li></ul></div></li><li class="half_rhythm"><div><b>Chemically Induced Tumor Model:</b>
|
||
<ul><li class="half_rhythm"><div>Colon cancer induced by chemical treatment with azoxymethane & dextran sulfate salt</div></li></ul></div></li><li class="half_rhythm"><div><b>Transgenic Models</b> (in collaboration with CAPR):
|
||
<ul><li class="half_rhythm"><div>Glioblastoma model (pRb/Kras/PTEN; Tamoxifen/Adeno-Cre; orthotopic)</div></li><li class="half_rhythm"><div>Lung cancer model (EGFR-L858R/T790M; Kras<sup>G12D</sup>/Lkb1; Kras<sup>G12D</sup>/p53EML4-ALK)</div></li><li class="half_rhythm"><div>Pancreatic ductal adenocancer model (Kras<sup>G12D</sup>/p53)</div></li><li class="half_rhythm"><div>Serous ovarian carcinoma (pRb/p53c/c or m/-;pRb/p53c/c or m/- /Brca1;prb/p53c/c or m/- /Brca2)</div></li><li class="half_rhythm"><div>Melanoma (HGF/MET; BRAFV600E)</div></li></ul></div></li></ul></div></li><li class="half_rhythm"><div class="half_rhythm"><u>Imaging</u></div><div class="half_rhythm">In collaboration with FNL’s Small Animal Imaging Program (SAIP), NCL has the capability to conduct efficacy studies in orthotopic and metastatic tumor models and noninvasively image tumor growth and measure therapeutic response using various imaging modalities, including bioluminescence and fluorescence imaging, PET/SPECT/CT, MRI, and ultrasound. Both in vivo/in situ and ex vivo/individual organ imaging is available upon request. In addition, efficacy of novel diagnostic or theragnostic nanoconstructs containing contrast agents can also be assessed utilizing the above-mentioned capabilities available at the SAIP.</div></li></ul></p></div><div id="ncipr78.s2.2"><h3>2. General Guidelines for Performing an Efficacy Study</h3><p>To determine the maximum tolerated dose and optimal dosing regimen of a therapeutic agent, it is ideal to perform dose-range finding studies and preliminary pharmacokinetic evaluation before conducting an in vivo efficacy experiment. These studies assist in estimating appropriate dosing schedules to attain therapeutic concentrations, while avoiding high toxic concentrations.</p><p>All cancer cell lines should be tested for human and rodent pathogens (HIV-1, HIV-2, HTLV-1, HTLV-2, Hepatitis B, Hepatitis C, CMV, EBV, JCV, and MoMuLV) prior to use in animal models, and animal study protocols (ASP) should be approved by an Institutional Animal Care and Use Committee (IACUC) prior to initiation of an animal study.</p><p>Appropriate control agents should be included in the study, such as standard-of-care treatment for a particular cancer type, free (unformulated, legacy) drug control, vehicle (formulation) control, or unloaded nanoparticle control (where applicable). Cytotoxic nanoformulations and comparator treatments should be dosed at equivalent doses and equitoxic MTD doses (<a href="/books/NBK604930/table/ncipr78.tab1/?report=objectonly" target="object" rid-ob="figobncipr78tab1">Table 1</a>; MTD defined as dose producing >20% body weight loss in 10% of animals). Doses should be based on initial dose-range finding study. An example of efficacy study design is shown below. Investigational nanoformulated API at two concentrations are compared with clinical formulation of API at an equitoxic and equivalent doses to reasonably estimate the therapeutic window of the nanoformulated API. If the nanoformulation has an attached targeting ligand, the inclusion of an untargeted nanoformulation will help identify targeting advantages. If the nanoformulation is a species-specific gene therapy (e.g. siRNA, plasmid DNA, antisense RNA, etc.), or contains species specific antibodies or ligands, utilizing a mouse ortholog of the relevant gene, antibody or ligand is important to allow assessment of side effects related to manipulation of the gene/protein/receptor in off target tissues. All preclinical studies should be performed using the clinical route and regimen of administration to best represent eventual clinical drug distribution and related efficacy and toxicities.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab1"><a href="/books/NBK604930/table/ncipr78.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img" rid-ob="figobncipr78tab1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab1"><a href="/books/NBK604930/table/ncipr78.tab1/?report=objectonly" target="object" rid-ob="figobncipr78tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">Example of Experimental Design for an Efficacy Study. Treatment groups, drug dose, number of animals, dose volumes, and dose schedule are displayed in the table below. Study drugs were administered by intravenous tail-vein, once every three days, for <a href="/books/NBK604930/table/ncipr78.tab1/?report=objectonly" target="object" rid-ob="figobncipr78tab1">(more...)</a></p></div></div><p>Depending on the cancer cell line and mouse strain, the tumor take rate and growth profile can vary significantly. A pilot tumor growth study is recommended to characterize the take rate and tumor growth profile prior to therapeutic evaluation. Once the tumors are of palpable size, the animals are randomized based on tumor volume and weight (<a href="/books/NBK604930/table/ncipr78.tab2/?report=objectonly" target="object" rid-ob="figobncipr78tab2">Tables 2</a> and <a href="/books/NBK604930/table/ncipr78.tab3/?report=objectonly" target="object" rid-ob="figobncipr78tab3">3</a>). The randomization process will remove any tumor size or body weight bias so the average tumor volume between treatment groups is not significant. The route of drug administration should reflect the anticipated clinical route of administration and regimen. The number of animals per treatment group required to achieve statistical power to detect a significance difference for a given treatment depends on the variability in tumor growth/survival and magnitude of the treatment response. Therefore, it is necessary to perform a pilot study to identify the variability in tumor growth/survival and anticipated magnitude of the treatment response. Assuming type I error (alpha) and type II error (Beta) are fixed at 5% (p<0.05) and <20%, respectively, then a simplified estimate of sample size for a tumor volume data (continuous variable) is given by [<a class="bk_pop" href="#ncipr78.ref1">1</a>]:
|
||
<div class="pmc_disp_formula whole_rhythm clearfix" id="ncipr78.deq1"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="ncipr78.eq1" display="block"><mtext>n</mtext><mo>=</mo><mn>1</mn><mo>+</mo><mn>2</mn><mtext>C</mtext><mo>×</mo><msup><mrow><mo stretchy="false">(</mo><mtext>s</mtext><mo>/</mo><mtext>d</mtext><mo stretchy="false">)</mo></mrow><mrow><mn>2</mn></mrow></msup></math></div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div>
|
||
where, s is standard deviation, d is the anticipated difference between control and treatment response, and the constant, C, is 7.85.</p><p>A simplified estimate of sample size for survival data (dichotomous variable) is given by:
|
||
<div class="pmc_disp_formula whole_rhythm clearfix" id="ncipr78.deq2"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="ncipr78.eq2" display="block"><mtext>N</mtext><mo>=</mo><mtext>C</mtext><mo>×</mo><mfenced><mrow><msub><mtext>p</mtext><mtext>c</mtext></msub><msub><mtext>q</mtext><mtext>c</mtext></msub><mo>+</mo><msub><mtext>p</mtext><mtext>t</mtext></msub><msub><mtext>p</mtext><mtext>t</mtext></msub><mo>/</mo><msup><mtext>d</mtext><mn>2</mn></msup></mrow></mfenced><mo>+</mo><mo stretchy="false">(</mo><mn>2</mn><mo>/</mo><mtext>d</mtext><mo stretchy="false">)</mo><mo>+</mo><mn>2</mn></math></div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div>
|
||
where, p<sub>c</sub> is the proportion of deaths in the contol group, q<sub>c</sub> is 1-p<sub>c,</sub>p<sub>t</sub> is the proportion of deaths in the treatment group, q<sub>t</sub> is 1-p<sub>t</sub>,d is the anticipated difference between the two groups, and the constant, C, is 7.85.</p><p>The sample size based on the above calculations are generally not greater than 10 animals for an implanted tumor model with a potent treatment response.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab2"><a href="/books/NBK604930/table/ncipr78.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img" rid-ob="figobncipr78tab2"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab2"><a href="/books/NBK604930/table/ncipr78.tab2/?report=objectonly" target="object" rid-ob="figobncipr78tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Example of Successful Animal Randomization by Tumor Volume. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab3"><a href="/books/NBK604930/table/ncipr78.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img" rid-ob="figobncipr78tab3"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab3"><a href="/books/NBK604930/table/ncipr78.tab3/?report=objectonly" target="object" rid-ob="figobncipr78tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Example of Successful Animal Randomizatio. </p></div></div></div><div id="ncipr78.s2.3"><h3>3. General Guidelines for Data Analysis From an Efficacy Study</h3><p>Trends can be observed by plotting tumor volume and body weight data as mean ± standard deviation or as percent change from initial volume/body weight (100%). Statistical differences in tumor volume and body weight values between groups can be determined using ANOVA, with appropriate post-hoc comparisons. Group time-to-endpoint or survival data are commonly analyzed by the Kaplan-Meier analysis, with the log-rank (Mantel-Cox) test to determine statistical significance.</p><p>Tumor volume and body weight analysis (<a href="/books/NBK604930/table/ncipr78.tab4/?report=objectonly" target="object" rid-ob="figobncipr78tab4">Table 4</a>) for study time points which contain <b>equal numbers</b> of animals in each group can be analyzed by ANOVA, with post-hoc comparison using either Dunnett’s Test for statistical significance in comparison to the control (<a href="/books/NBK604930/table/ncipr78.tab5/?report=objectonly" target="object" rid-ob="figobncipr78tab5">Table 5</a>) or the Duncan’s Test for statistical significance between all treatment groups (<a href="/books/NBK604930/table/ncipr78.tab6/?report=objectonly" target="object" rid-ob="figobncipr78tab6">Table 6</a>).</p><p>For study time points which contain <b>unequal numbers</b> of animals, tumor volume and body weight measurements over the study can be analyzed for statistical significance using ANOVA, with post-hoc comparisons by Tukey’s HSD Test (<a href="/books/NBK604930/table/ncipr78.tab7/?report=objectonly" target="object" rid-ob="figobncipr78tab7">Table 7</a>). Unequal sample sizes are often observed in survival studies, or time-to-endpoint studies in which animals are terminated at set neoplasia (tumor diameter reaching ≥2 cm or tumor ulceration) or morbidity (loss of ≥20% of an initial body weight and or immobility) criteria, as opposed to a set termination day. In this case, the number of animals per treatment group will vary over the course of the study due to differences in animal survival, or time to reach neoplasia or morbidity-related endpoints.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab4"><a href="/books/NBK604930/table/ncipr78.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img" rid-ob="figobncipr78tab4"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab4"><a href="/books/NBK604930/table/ncipr78.tab4/?report=objectonly" target="object" rid-ob="figobncipr78tab4">Table 4</a></h4><p class="float-caption no_bottom_margin">Example of Tumor Volume and Animal Body Weight Data. Tumor volume and body weight data for all the treatment groups are shown below and statistical analysis was conducted on this dataset (Tables 5 and 6 show statistical outputs). </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab5"><a href="/books/NBK604930/table/ncipr78.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img" rid-ob="figobncipr78tab5"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab5"><a href="/books/NBK604930/table/ncipr78.tab5/?report=objectonly" target="object" rid-ob="figobncipr78tab5">Table 5</a></h4><p class="float-caption no_bottom_margin">Example of Statistical Output Using Dunnett’s Test (significance in comparison to control group). </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab6"><a href="/books/NBK604930/table/ncipr78.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img" rid-ob="figobncipr78tab6"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab6"><a href="/books/NBK604930/table/ncipr78.tab6/?report=objectonly" target="object" rid-ob="figobncipr78tab6">Table 6</a></h4><p class="float-caption no_bottom_margin">Example of Statistical Output Using Duncan’s Test (significance in comparison to other treatment groups). </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab7"><a href="/books/NBK604930/table/ncipr78.tab7/?report=objectonly" target="object" title="Table 7" class="img_link icnblk_img" rid-ob="figobncipr78tab7"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab7"><a href="/books/NBK604930/table/ncipr78.tab7/?report=objectonly" target="object" rid-ob="figobncipr78tab7">Table 7</a></h4><p class="float-caption no_bottom_margin">Example of Statistical Output Using Tukey HSD Test. </p></div></div><p>Kaplan-Meier analyses of time-to-endpoint and survival data allows for censoring of data. Censoring of non-neoplasia-related endpoints, such as body weight endpoint (loss of ≥20% of an initial body weight) data, eliminates drug-related endpoints from the analysis of neoplasia-related endpoints (tumor diameter reaching ≥2 cm or tumor ulceration) (<a href="/books/NBK604930/table/ncipr78.tab8/?report=objectonly" target="object" rid-ob="figobncipr78tab8">Table 8</a>; <a class="figpopup" href="/books/NBK604930/figure/ncipr78.fig1/?report=objectonly" target="object" rid-figpopup="figncipr78fig1" rid-ob="figobncipr78fig1">Figure 1</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figncipr78fig1" co-legend-rid="figlgndncipr78fig1"><a href="/books/NBK604930/figure/ncipr78.fig1/?report=objectonly" target="object" title="Figure 1" class="img_link icnblk_img figpopup" rid-figpopup="figncipr78fig1" rid-ob="figobncipr78fig1"><img class="small-thumb" src="/books/NBK604930/bin/ncipr78f1.gif" src-large="/books/NBK604930/bin/ncipr78f1.jpg" alt="Example Kaplan-Meier survival plot" /></a><div class="icnblk_cntnt" id="figlgndncipr78fig1"><h4 id="ncipr78.fig1"><a href="/books/NBK604930/figure/ncipr78.fig1/?report=objectonly" target="object" rid-ob="figobncipr78fig1">Figure 1</a></h4><p class="float-caption no_bottom_margin">Kaplan-Meier Time to Endpoint Plots (body weight endpoint censored analysis). Kaplan-Meier time to endpoint plots for all the treatment groups. Asterisk indicates treatment groups 3, 4, and 6 are statistically significant (p ≤ 0.05, log-rank (Mantel-Cox) <a href="/books/NBK604930/figure/ncipr78.fig1/?report=objectonly" target="object" rid-ob="figobncipr78fig1">(more...)</a></p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab8"><a href="/books/NBK604930/table/ncipr78.tab8/?report=objectonly" target="object" title="Table 8" class="img_link icnblk_img" rid-ob="figobncipr78tab8"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab8"><a href="/books/NBK604930/table/ncipr78.tab8/?report=objectonly" target="object" rid-ob="figobncipr78tab8">Table 8</a></h4><p class="float-caption no_bottom_margin">Example of Kaplan-Meier Time-to-Endpoint Table (body weight endpoint censored). The remission codes are “1” for animals reaching a neoplasia-related endpoint, and “0” for censored animals which are euthanized due to drug-related <a href="/books/NBK604930/table/ncipr78.tab8/?report=objectonly" target="object" rid-ob="figobncipr78tab8">(more...)</a></p></div></div></div></div><div id="ncipr78.s3"><h2 id="_ncipr78_s3_">Toxicity Studies</h2><div id="ncipr78.s3.1"><h3>1. NCL Capabilities: Single or Repeat-Dose Toxicity Studies in Rodents</h3><p>In vivo toxicity studies at NCL are performed in collaboration with FNL’s Laboratory Animal Science Program. Each NCL <i>in vivo</i> study is tailored to the particular compound being tested, so each toxicity study is different, but in general we conduct single or repeat-dose toxicity tests, generally in both male and female rats or mice, generally by i.v. administration via tail vein injection. We monitor the animals usually for up to 14-days post dose, although sometimes longer if we expect delayed toxicities (28 days for immunotoxicity) or to accommodate longer treatment regimens (<a href="/books/NBK604930/table/ncipr78.tab9/?report=objectonly" target="object" rid-ob="figobncipr78tab9">Table 9</a>). We look for in-life changes in body weight or animal behavior, or changes, upon comprehensive necropsy, in organ weight, gross pathology, clinical chemistry, hematology, and histology of treatment groups relative to free/active drug, and vehicle or blank nanomedicine control groups. We evaluate major tissues (see list below) by gross pathology and histology, and conduct statistical analysis of lesion incidence and severity to determine differences between treatment and control groups. Advanced histological techniques such as special stains, immunohistochemistry, and in situ hybridization assays are also available, when applicable. We also conduct statistical analysis of body weight, organ weight (absolute, and body and brain weight normalized), and clinical chemistry and hematology parameters (see list below) to determine differences between groups. Regardless of the stealth properties of the nanomedicine, such as a PEGylated surface, there is often some distribution to organs of the RES, such as liver, spleen, lung, kidney, and these organs should receive special consideration in nanomedicine toxicity studies. There is concern about the long-term consequences of RES accumulation for non-biodegradable platforms, such as carbon-based, metallic and polymeric nanoparticles. In the case of selective distribution, such as RES sequestration or selective distribution of targeted nanoparticle, it may be necessary to perform repeat dose tissue distribution studies to identify accumulation [<a class="bk_pop" href="#ncipr78.ref2">2</a>].</p><p><u>Tissues Evaluated by Histopathology</u>
|
||
<ul><li class="half_rhythm"><div>adrenal</div></li><li class="half_rhythm"><div>brain</div></li><li class="half_rhythm"><div>cecum</div></li><li class="half_rhythm"><div>coagulating gland</div></li><li class="half_rhythm"><div>colon</div></li><li class="half_rhythm"><div>duodenum</div></li><li class="half_rhythm"><div>epididymis</div></li><li class="half_rhythm"><div>esophagus</div></li><li class="half_rhythm"><div>eye</div></li><li class="half_rhythm"><div>femoral artery</div></li><li class="half_rhythm"><div>femur</div></li><li class="half_rhythm"><div>gall bladder</div></li><li class="half_rhythm"><div>Harderian gland</div></li><li class="half_rhythm"><div>heart</div></li><li class="half_rhythm"><div>ileum</div></li><li class="half_rhythm"><div>jejunum</div></li><li class="half_rhythm"><div>kidney</div></li><li class="half_rhythm"><div>liver</div></li><li class="half_rhythm"><div>lung</div></li><li class="half_rhythm"><div>lymph node</div></li><li class="half_rhythm"><div>mammary gland</div></li><li class="half_rhythm"><div>muscle</div></li><li class="half_rhythm"><div>nasal sections</div></li><li class="half_rhythm"><div>ovary</div></li><li class="half_rhythm"><div>pancreas</div></li><li class="half_rhythm"><div>parathyroid</div></li><li class="half_rhythm"><div>pituitary</div></li><li class="half_rhythm"><div>prostate</div></li><li class="half_rhythm"><div>rectum</div></li><li class="half_rhythm"><div>salivary gland</div></li><li class="half_rhythm"><div>seminal vesicle</div></li><li class="half_rhythm"><div>skin/subcutis</div></li><li class="half_rhythm"><div>spinal cord</div></li><li class="half_rhythm"><div>spleen</div></li><li class="half_rhythm"><div>stomach (glandular/nonglandular)</div></li><li class="half_rhythm"><div>testis</div></li><li class="half_rhythm"><div>thymus</div></li><li class="half_rhythm"><div>thyroid</div></li><li class="half_rhythm"><div>tongue</div></li><li class="half_rhythm"><div>trachea</div></li><li class="half_rhythm"><div>urinary bladder</div></li><li class="half_rhythm"><div>uterus</div></li><li class="half_rhythm"><div>vertebra</div></li><li class="half_rhythm"><div>and any additional tissue with gross findings at necropsy</div></li></ul></p><p><u>Hematology Parameters Evaluated</u>
|
||
<ul><li class="half_rhythm"><div>blood smear</div></li><li class="half_rhythm"><div>differential leukocyte count (NE, LY, MO, EO, BA)</div></li><li class="half_rhythm"><div>erythrocyte count (RBC)</div></li><li class="half_rhythm"><div>hematocrit (HCT)</div></li><li class="half_rhythm"><div>hemoglobin (Hb)</div></li><li class="half_rhythm"><div>mean corpuscular hemoglobin (MCH)</div></li><li class="half_rhythm"><div>mean corpuscular hemoglobin concentration (MCHC)</div></li><li class="half_rhythm"><div>mean corpuscular volume (MCV)</div></li><li class="half_rhythm"><div>nucleated red blood cell count</div></li><li class="half_rhythm"><div>red blood cell distribution width (RDW)</div></li><li class="half_rhythm"><div>platelet count (PLT)</div></li><li class="half_rhythm"><div>mean platelet volume (MPV)</div></li><li class="half_rhythm"><div>reticulocyte count (RETIC)</div></li><li class="half_rhythm"><div>total leukocyte count (WBC)</div></li></ul></p><p><u>Clinical Chemistry Parameters Evaluated</u>
|
||
<ul><li class="half_rhythm"><div>alanine aminotransferase (ALT)</div></li><li class="half_rhythm"><div>albumin (ALB)</div></li><li class="half_rhythm"><div>albumin/globulin ratio (A/G)</div></li><li class="half_rhythm"><div>alkaline phosphatase (ALP)</div></li><li class="half_rhythm"><div>amylase (AMS)</div></li><li class="half_rhythm"><div>bilirubin, total (TBIL)</div></li><li class="half_rhythm"><div>blood urea nitrogen (BUN)</div></li><li class="half_rhythm"><div>calcium (Ca)</div></li><li class="half_rhythm"><div>chloride (Cl)</div></li><li class="half_rhythm"><div>creatinine (Cr)</div></li><li class="half_rhythm"><div>globulin (GLOB)</div></li><li class="half_rhythm"><div>glucose (GLUC)</div></li><li class="half_rhythm"><div>phosphate (PHOS)</div></li><li class="half_rhythm"><div>potassium (K)</div></li><li class="half_rhythm"><div>sodium (Na)</div></li><li class="half_rhythm"><div>total protein (TP)</div></li></ul></p></div><div id="ncipr78.s3.2"><h3>2. General Guidelines for Performing a Toxicity Study</h3><p>The doses used in the study depend on the expected clinical therapeutic dose, the available material, and the amount of material we can feasibly administer based on drug formulation concentration and administered volume limited by route. Ideally, we test the expected clinical dose (scaled by body weight or surface area to rats) and 10- and 100-fold times that dose. All NCL studies are conducted under non-GLP conditions, but ICH guidance indicates that non-GLP acute toxicity studies can be sufficient for an IND inclusion as long as repeat dose toxicity studies are conducted under GLP conditions.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab9"><a href="/books/NBK604930/table/ncipr78.tab9/?report=objectonly" target="object" title="Table 9" class="img_link icnblk_img" rid-ob="figobncipr78tab9"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab9"><a href="/books/NBK604930/table/ncipr78.tab9/?report=objectonly" target="object" rid-ob="figobncipr78tab9">Table 9</a></h4><p class="float-caption no_bottom_margin">Example of Experimental Design for a Multi-dose Toxicity Study. Treatment groups, drug dose, number of animals, dose volumes, and dose schedule are displayed in the table below. Study drugs were administered by intravenous tail-vein, once a day for seven <a href="/books/NBK604930/table/ncipr78.tab9/?report=objectonly" target="object" rid-ob="figobncipr78tab9">(more...)</a></p></div></div></div></div><div id="ncipr78.s4"><h2 id="_ncipr78_s4_">Pharmacokinetic Studies</h2><div id="ncipr78.s4.1"><h3>1. NCL Capabilities: Pharmacokinetic Studies in Rodents</h3><p>The ability of nanoformulations to alter drug pharmacokinetics and tissue distribution, and thereby change drug efficacy and toxicity, is the most fundamental concept in the field of nanomedicine. Thus, understanding the pharmacokinetics and biodistribution of nanomedicines is very important, because it allows for formulation optimization, selection of dose and dosing regimens, establishment of PKPD relationships, and identification of likely target organs of toxicity to concentrate on in toxicity studies. The FDA has recommended that nanomedicines undergo comparative pharmacokinetic and mass balance studies with marketed formulations in order to identify differences in drug disposition [<a class="bk_pop" href="#ncipr78.ref3">3</a>], and we will often compare the nanoformulated drug to the conventionally formulated, marketed version of the drug.</p><p>We typically conduct pharmacokinetic, and biodistribution studies, in male double-jugular-catheterized Sprague Dawley rats, although we have also conducted studies in intact (non-catheterized) mice when appropriate (<a href="/books/NBK604930/table/ncipr78.tab10/?report=objectonly" target="object" rid-ob="figobncipr78tab10">Tables 10</a> and <a href="/books/NBK604930/table/ncipr78.tab11/?report=objectonly" target="object" rid-ob="figobncipr78tab11">11</a>). Catheters allow for accurate dose administration and easy blood draws. We choose rats as our primary model, as rats are the most common rodent species used in IND-enabling GLP toxicity and toxicokinetic studies. Rats also allow for more blood volume to be removed than mice, and mouse PK studies often utilize a single mouse per time point as opposed to multiple blood draws from the same mouse Although techniques like “tail tipping” or submandibular vein collection can allow for multiple murine blood collections, the actual resulting plasma volumes can be quite small, ~50 μL, and this can limit bioanalytical assay sensitivity. It is, however, important to note that mouse PK studies, with a single time point per mouse, does allow for tissue collection at each time point as well, and this would be advantageous for a combined PK biodistribution study. Also, importantly, as the average mouse weighs 1/10<sup>th</sup> the average rat, even if you have to dose one mouse per time point, the overall dose would be the same assuming 10 time points and the same animal number, <i>N,</i> at each time point. The primary draw back with the one mouse per time point study is the data at each time point will be more variable than if the data had come from a rat study with multiple time points from the same rat.</p></div><div id="ncipr78.s4.2"><h3>2. General Guidelines for Performing a Pharmacokinetic Study</h3><p>The dose for a PK study should be non-toxic (unless this is a toxicokinetic study to relate toxicity to drug exposure as part of a toxicity study), but high enough to allow for drug quantification, which is dependent on the bioanalytical assay sensitivity. Additionally, pharmacokinetic studies should use at least two doses, 5-10 fold apart, in order to estimate the linearity of the pharmacokinetics with respect to dose.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab10"><a href="/books/NBK604930/table/ncipr78.tab10/?report=objectonly" target="object" title="Table 10" class="img_link icnblk_img" rid-ob="figobncipr78tab10"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab10"><a href="/books/NBK604930/table/ncipr78.tab10/?report=objectonly" target="object" rid-ob="figobncipr78tab10">Table 10</a></h4><p class="float-caption no_bottom_margin">Example of Experimental Design for a Rat Pharmacokinetic/Biodistribution Study. Treatment groups, drug dose, number of animals, dose volumes, and dose schedule are displayed in the table below. Study drugs were administered as a single i.v. bolus via <a href="/books/NBK604930/table/ncipr78.tab10/?report=objectonly" target="object" rid-ob="figobncipr78tab10">(more...)</a></p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figncipr78tab11"><a href="/books/NBK604930/table/ncipr78.tab11/?report=objectonly" target="object" title="Table 11" class="img_link icnblk_img" rid-ob="figobncipr78tab11"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="ncipr78.tab11"><a href="/books/NBK604930/table/ncipr78.tab11/?report=objectonly" target="object" rid-ob="figobncipr78tab11">Table 11</a></h4><p class="float-caption no_bottom_margin">Example of Experimental Design for a Mouse Pharmacokinetic/Biodistribution Study. Treatment groups, drug dose, number of animals, dose volumes, and dose schedule are displayed in the table below. Study drugs were administered as a single i.v. bolus tail <a href="/books/NBK604930/table/ncipr78.tab11/?report=objectonly" target="object" rid-ob="figobncipr78tab11">(more...)</a></p></div></div><p>When selecting time points for the study, it is important to try to capture all the distribution phases, absorption (if extravascular route), tissue distribution and terminal elimination. A good rule of thumb is that the area under the time concentration curve all time points, AUCall, should be within 15% of the extrapolated to time infinity AUC, AUCinf; this requires that sufficient time points be selected at the terminal phase to cover the majority of that phase. Capturing each phase sufficiently with the time points selected will also allow better estimation of the slopes of these phases and allow determination if there are multiple phases for each process, such as two tissue distribution phases, as can often occur.</p><p>The primary complexity of nanomedicine pharmacokinetics in comparison to conventional drug formulation, is the necessity to measure both the nanomedicine-encapsulated drug, i.e. the encapsulated drug fraction, as well as the unencapsulated drug fraction. All too often, nanomedicine pharmacokinetic studies only measure the total drug systemically, or in tissue, which is a composite of both the encapsulated and unencapsulated drug. Generally, for a stable nanomedicine drug complex, the blood/plasma and tissue will be dominated by the encapsulated drug fraction, which will be primarily represented in the total drug concentration estimate.</p><p>Methods to fractionate PK samples and allow determination of encapsulated and unencapsulated drug include dialysis, liquid-liquid extraction, solid phase extraction, size exclusion chromatography, and ultrafiltration (for review see [<a class="bk_pop" href="#ncipr78.ref4">4</a>]). The method most often used by our laboratory, which was invented in our lab, is the stable isotope tracer ultrafiltration assay, or SITUA [<a class="bk_pop" href="#ncipr78.ref5">5</a>]. Apart from these methods to measure drug fractions, dual labeling, and complementary and orthogonal techniques to measure both drug and nanoplatform have also been used to determine platform stability and drug release, and estimate encapsulated and unencapsulated drug fractions. These alternative methods include dual labeling and modeling to estimate drug fractions; dual labels can include radioactive of fluorescent labels, such as tritium labeled platform and <sup>14</sup>C labeled drug. Similar PK of the nanoplatform and drug labels would suggest platform stability, while disparate PK would suggest instability [<a class="bk_pop" href="#ncipr78.ref6">6</a>].</p><p>Complementary analysis involves complementary techniques, such as quantitative chemical and/or biochemical analysis, for measurement of the platform and payload, such as enzyme linked immunosorbent assay (ELISA) to measure a biological payload and inductively coupled plasma mass spectrometry (ICP-MS) measure a metallic platform. By modeling disparate platform and drug profiles, with knowledge of the free drug PK, the encapsulated and unencapsulated drug profiles can be estimated, as well as the drug release kinetics [<a class="bk_pop" href="#ncipr78.ref7">7</a>]. Modeling and simulation of nanomedicine metabolite data can also be used to estimate encapsulated and unencapsulated drug profiles [<a class="bk_pop" href="#ncipr78.ref8">8</a>].</p></div></div><div id="ncipr78.rl.r1"><h2 id="_ncipr78_rl_r1_">References</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="ncipr78.ref1">H.
|
||
Shah, How to calculate sample size in animal studies?
|
||
Natl J Physiol Pharm Pharmacol. 1 (2015) 35–39.</div></dd><dt>2.</dt><dd><div class="bk_ref" id="ncipr78.ref2">Guideline for Industry, Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); Rockville, MD: Mar
|
||
1995. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s3b-pharmacokinetics-guidance-repeated-dose-tissue-distribution-studies" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Link</a>.</div></dd><dt>3.</dt><dd><div class="bk_ref" id="ncipr78.ref3">Guidance for Industry, Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); Rockville, MD: Apr
|
||
2018. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/liposome-drug-products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Link</a>.</div></dd><dt>4.</dt><dd><div class="bk_ref" id="ncipr78.ref4">V.V.
|
||
Ambardekar, S.T.
|
||
Stern, NBCD Pharmacokinetics and Drug Release Methods, in: D.J.A.
|
||
Crommelin, J.S.B.
|
||
de Vlieger (Eds.) Non-Biological Complex Drugs; The Science and the Regulatory Landscape, Springer International Publishing
|
||
2015, pp. 261–287.</div></dd><dt>5.</dt><dd><div class="bk_ref" id="ncipr78.ref5">S.
|
||
Skoczen, S.E.
|
||
McNeil, S.T.
|
||
Stern, Stable isotope method to measure drug release from nanomedicines, J Control Release, 220 (2015) 169–174.
|
||
[<a href="/pmc/articles/PMC4688069/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4688069</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26596375" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26596375</span></a>]</div></dd><dt>6.</dt><dd><div class="bk_ref" id="ncipr78.ref6">B.S.
|
||
Zolnik, S.T.
|
||
Stern, J.M.
|
||
Kaiser, Y.
|
||
Heakal, J.D.
|
||
Clogston, M.
|
||
Kester, S.E.
|
||
McNeil, Rapid distribution of liposomal short-chain ceramide in vitro and in vivo, Drug Metab Dispos, 36 (2008) 1709–1715.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/18490436" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18490436</span></a>]</div></dd><dt>7.</dt><dd><div class="bk_ref" id="ncipr78.ref7">S.T.
|
||
Stern, J.B.
|
||
Hall, L.L.
|
||
Yu, L.J.
|
||
Wood, G.F.
|
||
Paciotti, L.
|
||
Tamarkin, S.E.
|
||
Long, S.E.
|
||
McNeil, Translational considerations for cancer nanomedicine, J Control Release, 146 (2010) 164–174.
|
||
[<a href="/pmc/articles/PMC2921639/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2921639</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20385183" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20385183</span></a>]</div></dd><dt>8.</dt><dd><div class="bk_ref" id="ncipr78.ref8">S.T.
|
||
Stern, P.
|
||
Zou, S.
|
||
Skoczen, S.
|
||
Xie, B.
|
||
Liboiron, T.
|
||
Harasym, P.
|
||
Tardi, L.D.
|
||
Mayer, S.E.
|
||
McNeil, Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion, J Control Release, 172 (2013) 558–567.
|
||
[<a href="/pmc/articles/PMC3788091/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3788091</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23664969" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23664969</span></a>]</div></dd></dl></div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_top_margin"><div>
|
||
<strong>Contact</strong>
|
||
</div><div>For more information or to discuss questions pertaining to your specific nanoformulation, please reach out to NCL’s Head of Pharmacology & Toxicology, Dr. Stephan Stern:</div><div>Stephan T. Stern, PhD, DABT</div><div>Director of Research & Development, Head of Pharmacology & Toxicology Section</div><div>Nanotechnology Characterization Laboratory</div><div>
|
||
<a href="mailto:dev@null" data-email="vog.hin.liam@nahpetsnrets" class="oemail">vog.hin.liam@nahpetsnrets</a>
|
||
</div></p></div></dd></dl></div><div id="bk_toc_contnr"></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK604930</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39013071" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">39013071</a></span>DOI: <a href="http://dx.crossref.org/10.17917/W63A-GR02" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">10.17917/W63A-GR02</a></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/nciprotocols/">Contents</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/nciprotocols/ncipr18/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/nciprotocols/ncipr32/" title="Next page in this title">Next ></a></div></div></div></div>
|
||
|
||
</div>
|
||
|
||
<!-- Custom content below content -->
|
||
<div class="col4">
|
||
|
||
</div>
|
||
|
||
|
||
<!-- Book content -->
|
||
|
||
<!-- Custom contetnt below bottom nav -->
|
||
<div class="col5">
|
||
|
||
</div>
|
||
</div>
|
||
|
||
<div id="rightcolumn" class="four_col col last">
|
||
<!-- Custom content above discovery portlets -->
|
||
<div class="col6">
|
||
<div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK604930&db=books">Share</a></div>
|
||
|
||
</div>
|
||
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK604930/?report=reader">PubReader</a></li><li><a href="/books/NBK604930/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK604930" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK604930" style="display:none" title="Cite this Page"><div class="bk_tt">Stephan T. S. Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology. 2022 Sep. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1-. <span class="bk_cite_avail"></span> doi: 10.17917/W63A-GR02</div></div></li><li><a href="/books/NBK604930/pdf/Bookshelf_NBK604930.pdf">PDF version of this page</a> (520K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this Page</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ncipr78.s1" ref="log$=inpage&link_id=inpage">Introduction</a></li><li><a href="#ncipr78.s2" ref="log$=inpage&link_id=inpage">Efficacy Studies</a></li><li><a href="#ncipr78.s3" ref="log$=inpage&link_id=inpage">Toxicity Studies</a></li><li><a href="#ncipr78.s4" ref="log$=inpage&link_id=inpage">Pharmacokinetic Studies</a></li><li><a href="#ncipr78.rl.r1" ref="log$=inpage&link_id=inpage">References</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&DbFrom=books&Cmd=Link&LinkName=books_pmc_refs&IdsFromResult=5640874" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&DbFrom=books&Cmd=Link&LinkName=books_pubmed_refs&IdsFromResult=5640874" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28846237" ref="ordinalpos=1&linkpos=1&log$=relatedarticles&logdbfrom=pubmed">Case Control Studies.</a><span class="source">[StatPearls. 2025]</span><div class="brieflinkpop offscreen_noflow">Case Control Studies.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tenny S, Kerndt CC, Hoffman MR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">StatPearls. 2025 Jan</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/39718517" ref="ordinalpos=1&linkpos=2&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review.</a><span class="source">[Gastroenterology. 2025]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shah SC, Wang AY, Wallace MB, Hwang JH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Gastroenterology. 2025 Feb; 168(2):405-416.e1. Epub 2024 Dec 23.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/36321689" ref="ordinalpos=1&linkpos=3&log$=relatedarticles&logdbfrom=pubmed">Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.</a><span class="source">[Health Technol Assess. 2022]</span><div class="brieflinkpop offscreen_noflow">Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Elwenspoek MM, Thom H, Sheppard AL, Keeney E, O'Donnell R, Jackson J, Roadevin C, Dawson S, Lane D, Stubbs J, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Health Technol Assess. 2022 Oct; 26(44):1-310. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/38174816" ref="ordinalpos=1&linkpos=4&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).</a><span class="source">[Cochrane Database Syst Rev. 2024]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ngwenya O, Lensen SF, Vail A, Mol BWJ, Broekmans FJ, Wilkinson J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cochrane Database Syst Rev. 2024 Jan 4; 1(1):CD012693. Epub 2024 Jan 4.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/38511668" ref="ordinalpos=1&linkpos=5&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Community views on active case finding for tuberculosis in low- and middle-income countries: a qualitative evidence synthesis.</a><span class="source">[Cochrane Database Syst Rev. 2024]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Community views on active case finding for tuberculosis in low- and middle-income countries: a qualitative evidence synthesis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Taylor M, Medley N, van Wyk SS, Oliver S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cochrane Database Syst Rev. 2024 Mar 21; 3(3):CD014756. Epub 2024 Mar 21.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed_reviews&uid=39013071" ref="ordinalpos=1&log$=relatedreviews_seeall&logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=39013071" ref="ordinalpos=1&log$=relatedarticles_seeall&logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=67c80a66d5edb449bf60092f">Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology - National...</a><div class="ralinkpop offscreen_noflow">Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=2" href="/portal/utils/pageresolver.fcgi?recordid=67c80a65feee5b00ac1cdb17">Leukocyte Proliferation Assay - National Cancer Institute’s Nanotechnology Chara...</a><div class="ralinkpop offscreen_noflow">Leukocyte Proliferation Assay - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=3" href="/portal/utils/pageresolver.fcgi?recordid=67c80a64feee5b00ac1cd4b3">Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay - National Cancer Institute’s...</a><div class="ralinkpop offscreen_noflow">Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=4" href="/portal/utils/pageresolver.fcgi?recordid=67c80a63d5edb449bf5fe9f2">Phagocytosis Assay - National Cancer Institute’s Nanotechnology Characterization...</a><div class="ralinkpop offscreen_noflow">Phagocytosis Assay - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=5" href="/portal/utils/pageresolver.fcgi?recordid=67c80a616d1ec11b6f7c07ba">Endotoxin & Depyrogenation Tips - National Cancer Institute’s Nanotechnology Cha...</a><div class="ralinkpop offscreen_noflow">Endotoxin & Depyrogenation Tips - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
|
||
|
||
<!-- Custom content below discovery portlets -->
|
||
<div class="col7">
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Custom content after all -->
|
||
<div class="col8">
|
||
|
||
</div>
|
||
<div class="col9">
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
|
||
<script type="text/javascript">
|
||
(function($){
|
||
$('.skiplink').each(function(i, item){
|
||
var href = $($(item).attr('href'));
|
||
href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
|
||
$(item).on('click', function(event){
|
||
event.preventDefault();
|
||
$.scrollTo(href, 0, {
|
||
onAfter: function(){
|
||
href.focus();
|
||
}
|
||
});
|
||
});
|
||
});
|
||
})(jQuery);
|
||
</script>
|
||
</div>
|
||
<div class="bottom">
|
||
<script type="text/javascript">
|
||
var PBooksSearchTermData = {
|
||
highlighter: "bold",
|
||
dateTime: "03/05/2025 03:12:13",
|
||
terms: [
|
||
'2010'
|
||
]
|
||
};
|
||
</script>
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<div class="footer" id="footer">
|
||
<section class="icon-section">
|
||
<div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
|
||
<div class="grid-container container">
|
||
<div class="icon-section_container">
|
||
<a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<defs>
|
||
<style>
|
||
.cls-11 {
|
||
fill: #737373;
|
||
}
|
||
</style>
|
||
</defs>
|
||
<title>Twitter</title>
|
||
<path class="cls-11" d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
|
||
</path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<title>Facebook</title>
|
||
<path class="cls-11" d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
|
||
</path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_linkedin" href="https://www.linkedin.com/company/ncbinlm" aria-label="LinkedIn"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<title>LinkedIn</title>
|
||
<path class="cls-11" d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
|
||
</path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<defs>
|
||
<style>
|
||
.cls-11,
|
||
.cls-12 {
|
||
fill: #737373;
|
||
}
|
||
|
||
.cls-11 {
|
||
fill-rule: evenodd;
|
||
}
|
||
</style>
|
||
</defs>
|
||
<title>GitHub</title>
|
||
<path class="cls-11" d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
|
||
</path>
|
||
<path class="cls-12" d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
|
||
</path>
|
||
<path class="cls-12" d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
|
||
</path>
|
||
<path class="cls-12" d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
|
||
<path class="cls-12" d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
|
||
</path>
|
||
<path class="cls-12" d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
|
||
</path>
|
||
<path class="cls-12" d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
|
||
</path>
|
||
<path class="cls-12" d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
|
||
<svg xmlns="http://www.w3.org/2000/svg" id="Layer_1" data-name="Layer 1" viewBox="0 0 40 40">
|
||
<defs><style>.cls-1{fill:#737373;}</style></defs>
|
||
<title>NCBI Insights Blog</title>
|
||
<path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"></path>
|
||
</svg>
|
||
</a>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<section class="container-fluid bg-primary">
|
||
<div class="container pt-5">
|
||
<div class="row mt-3">
|
||
<div class="col-lg-3 col-12">
|
||
<p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
|
||
<ul class="list-inline social_media">
|
||
<li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
||
<style type="text/css">
|
||
.st20 {
|
||
fill: #FFFFFF;
|
||
}
|
||
|
||
.st30 {
|
||
fill: none;
|
||
stroke: #FFFFFF;
|
||
stroke-width: 8;
|
||
stroke-miterlimit: 10;
|
||
}
|
||
</style>
|
||
<title>Twitter</title>
|
||
<g>
|
||
<g>
|
||
<g>
|
||
<path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7 c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116 c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3 c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6 C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
|
||
</g>
|
||
</g>
|
||
<circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
|
||
</g>
|
||
</svg></a></li>
|
||
<li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine" aria-label="Facebook" rel="noopener noreferrer" target="_blank">
|
||
<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
||
<style type="text/css">
|
||
.st10 {
|
||
fill: #FFFFFF;
|
||
}
|
||
|
||
.st110 {
|
||
fill: none;
|
||
stroke: #FFFFFF;
|
||
stroke-width: 8;
|
||
stroke-miterlimit: 10;
|
||
}
|
||
</style>
|
||
<title>Facebook</title>
|
||
<g>
|
||
<g>
|
||
<path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9 v67.5H135v-67.5h21.7L159,99.1z"></path>
|
||
</g>
|
||
</g>
|
||
<circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
|
||
</svg>
|
||
</a></li>
|
||
<li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
||
<title>Youtube</title>
|
||
<style type="text/css">
|
||
.st4 {
|
||
fill: none;
|
||
stroke: #FFFFFF;
|
||
stroke-width: 8;
|
||
stroke-miterlimit: 10;
|
||
}
|
||
|
||
.st5 {
|
||
fill: #FFFFFF;
|
||
}
|
||
</style>
|
||
<circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
|
||
<g transform="translate(0,-952.36218)">
|
||
<path class="st5" d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7 v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
|
||
</g>
|
||
</svg></a></li>
|
||
</ul>
|
||
</div>
|
||
<div class="col-lg-3 col-12">
|
||
<p class="address_footer text-white">National Library of Medicine<br />
|
||
<a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323" class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br />
|
||
Bethesda, MD 20894</a></p>
|
||
</div>
|
||
<div class="col-lg-3 col-12 centered-lg">
|
||
<p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br />
|
||
<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="text-white">FOIA</a><br />
|
||
<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
|
||
</div>
|
||
<div class="col-lg-3 col-12 centered-lg">
|
||
<p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br />
|
||
<a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br />
|
||
<a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
|
||
</div>
|
||
</div>
|
||
<div class="row">
|
||
<div class="col-lg-12 centered-lg">
|
||
<nav class="bottom-links">
|
||
<ul class="mt-3">
|
||
<li>
|
||
<a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
|
||
</li>
|
||
<li>
|
||
<a class="text-white" href="https://www.nih.gov/">NIH</a>
|
||
</li>
|
||
<li>
|
||
<a class="text-white" href="https://www.hhs.gov/">HHS</a>
|
||
</li>
|
||
<li>
|
||
<a class="text-white" href="https://www.usa.gov/">USA.gov</a>
|
||
</li>
|
||
</ul>
|
||
</nav>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK604930&ncbi_domain=nciprotocols&ncbi_report=record&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK604930/&ncbi_pagename=Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols - NCBI Bookshelf&ncbi_bookparttype=chapter&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4209313/4212053/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |